MYO15A

Across TCGA pan-cancer cohorts, MYO15A Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MYO15A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MYO15A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO15A expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

KIRP, UCEC, and ACC are the cancer types where MYO15A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.427	0.907	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.961	0.410	<.001	36	view →
ACC	DFS	Median	All	0.128	0.680	<.001	21	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
COAD	OS	Median	All	0.867	0.490	.005	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	OS	Median	All	0.233	0.738	<.001	9	view →
CESC	OS	Median	All	1.000	0.565	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MYO15A–KIRP (OS)

Open the KIRP breakdown →